Hourly refreshMon, Sep 14, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Healthcare

7,221 press releases indexed under healthcare.

AllFinanceCryptoAISaaSHealthcareReal EstateEnergyRetailAutomotiveGamingMediaEducation
DownloadExcelTXT
Healthcare

DEFY IT Health Kratom Reviews 2026: Is Level-Up or Respawn the Better Fit for Your Routine? 7-OH, Pricing & Ingredients Examined

As interest in whole-leaf kratom and 7-OH continues shaping buyer research in 2026, this DEFY IT Health Kratom review examines Level-Up vs. Respawn, the brand-stated *Mitragyna speciosa* ingredient profile, current pricing, batch-testing disclosures, refund terms, and the key differences consumers may want to compare before choosing a format for their routine.

Sep 5 · 00:35Newswire.com
Healthcare

Mark Kaire Recognized in 2027 Edition of The Best Lawyers in America(R)

Aventura attorney recognized for work in personal injury litigation and medical malpractice law for plaintiffs

Sep 4 · 23:20Newswire.com
Finance · Healthcare

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical congress.

Sep 4 · 23:05GlobeNewswire
SaaS · Healthcare

Amwell Receives Frost & Sullivan's 2026 United States Technology Innovation Leadership Recognition for Technology-Enabled Care Platforms

Amwell® is transforming virtual care delivery through its unified Amwell Platform, combining interoperability, clinical integration, and intelligent orchestration to improve access, efficiency, and outcomes. SAN ANTONIO, Sept. 4, 2026 /PRNewswire/ -- As healthcare organizations move...

Sep 4 · 22:26PR Newswire
Finance · Healthcare

Pomerantz LLP Commences Class Action Against Fractyl Health, Inc. – ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..

Sep 4 · 22:02PR-Inside
Healthcare

Conavi Medical Announces Media and Digital Marketing Agreements

TORONTO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has entered into media and digital marketing agreements to support increased market awareness of the Company.

Sep 4 · 22:02GlobeNewswire
Healthcare

Postpartum Support International Calls for Reform as Lindsay Clancy Case Ends in Mistrial

PORTLAND, Ore., Sept. 4, 2026 /PRNewswire/ -- Postpartum Support International, the nation's leading nonprofit dedicated to perinatal mental health, believes the decision to try Lindsay Clancy for first-degree murder demands that we, as a society, confront an uncomfortable truth. The...

Sep 4 · 20:31PR Newswire
Finance · Healthcare

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the “Grant Date”), ORIC granted a total of 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who began their employment with ORIC in August 2026.

Sep 4 · 20:30GlobeNewswire
Finance · Healthcare

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Sep 4 · 20:05GlobeNewswire
Finance · Healthcare

Kaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 2, 2026

New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may...

Sep 4 · 20:05mlpr-newsfile
Finance · Healthcare

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio’s common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Sep 4 · 20:05GlobeNewswire
Healthcare

In-Home Personal Training for Seniors Grows in Ontario as HomeStretch Active Living Marks One Year

HomeStretch Active Living expanded from B.C. into Ontario in August 2025 with one kinesiologist. One year later, eleven deliver in-home personal training for seniors. The post In-Home Personal Training for Seniors Grows in Ontario as HomeStretch Active Living Marks One Year first appeared on

Sep 4 · 19:19PRUnderground
← Prev123602Next →